Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoMatryx neoadjuvant cemiplimab trial in Merkel cell carcinoma
2025-522091-84-00Phase 2Authorised
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- May 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Merkel cell carcinoma (MCC) comparing Neoadjuvant Libtayo with Placebo (2 arms). Primary endpoint: Nodal micrometastases-free rate. Planned start May 2026; status: authorised.
02
Drugs
cemiplimab
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on 2025-522091-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522091-84-00.